Subscribe Sign In Register

Premium

How ValueAct Shook Off Its Big Loss from Valeant

The hedge fund firm, headed by Jeff Ubben, did not suffer the same fate as other major shareholders of the ailing pharmaceutical concern.

By Stephen Taub Stephen Taub
January 6, 2017
Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016. Valeant Pharmaceuticals International Inc. is scheduled to release earnings figures on Aug. 9. Photographer: Ron Antonelli/Bloomberg

Ron Antonelli/Bloomberg

Valeant Pharmaceuticals Offices Ahead Of Earnings Figures

Valeant Pharmaceuticals International Inc. headquarters stands in Bridgewater Township, New Jersey, U.S., on Thursday, Aug. 4, 2016.

To continue reading, subscribe now to Premium Journalism. Already a subscriber? login.

Pharmaceutical Valueact Jeff Ubben Valiant
Related
Art_Immunovant_0928.jpg
Premium
The Hedge Fund Winners From Immunovant’s Rise
Stephen Taub
September 28, 2023
Art_59North_0922.jpg
Premium
Here’s Why Michael Bilger’s 59 North Has Been One of the Top Launches in Recent Years
Stephen Taub
September 27, 2023
Pitchbook-EU-ins-cover.png
Sponsored
Morningstar’s Top Two Picks in EU Insurers